142 related articles for article (PubMed ID: 31977455)
1. The Complementary Role of 68Ga-DOTATATE PET/CT in Neuroblastoma.
Telli T; Lay Ergün E; Volkan Salanci B; Özgen Kiratli P
Clin Nucl Med; 2020 Apr; 45(4):326-329. PubMed ID: 31977455
[TBL] [Abstract][Full Text] [Related]
2.
AlSadi R; Maaz AUR; Bouhali O; Djekidel M
J Nucl Med Technol; 2023 Jun; 51(2):140-146. PubMed ID: 37192823
[No Abstract] [Full Text] [Related]
3. 68Ga-DOTATATE uptake in pineal gland, a rare physiological variant: case series.
Riaz S; Syed R; Skoura E; Alshammari A; Gaze M; Sajjan R; Halsey R; Bomanji J
Ann Nucl Med; 2015 Nov; 29(9):833-7. PubMed ID: 26173444
[TBL] [Abstract][Full Text] [Related]
4.
Maaz AUR; O'Doherty J; Djekidel M
J Nucl Med Technol; 2021 Sep; 49(3):265-268. PubMed ID: 33820858
[TBL] [Abstract][Full Text] [Related]
5. Feasibility and Therapeutic Potential of Combined Peptide Receptor Radionuclide Therapy With Intensive Chemotherapy for Pediatric Patients With Relapsed or Refractory Metastatic Neuroblastoma.
Fathpour G; Jafari E; Hashemi A; Dadgar H; Shahriari M; Zareifar S; Jenabzade AR; Vali R; Ahmadzadehfar H; Assadi M
Clin Nucl Med; 2021 Jul; 46(7):540-548. PubMed ID: 33782280
[TBL] [Abstract][Full Text] [Related]
6. 68Ga-DOTATATE and 123I-mIBG as imaging biomarkers of disease localisation in metastatic neuroblastoma: implications for molecular radiotherapy.
Gains JE; Aldridge MD; Mattoli MV; Bomanji JB; Biassoni L; Shankar A; Gaze MN
Nucl Med Commun; 2020 Nov; 41(11):1169-1177. PubMed ID: 32796449
[TBL] [Abstract][Full Text] [Related]
7. 68Ga-DOTA-TATE in Neuroblastoma With Marrow Involvement.
Torun N
Clin Nucl Med; 2019 Jun; 44(6):467-468. PubMed ID: 30889003
[TBL] [Abstract][Full Text] [Related]
8. Review: The Role of Radiolabeled DOTA-Conjugated Peptides for Imaging and Treatment of Childhood Neuroblastoma.
Alexander N; Vali R; Ahmadzadehfar H; Shammas A; Baruchel S
Curr Radiopharm; 2018; 11(1):14-21. PubMed ID: 29243585
[TBL] [Abstract][Full Text] [Related]
9. 177Lu-DOTATATE molecular radiotherapy for childhood neuroblastoma.
Gains JE; Bomanji JB; Fersht NL; Sullivan T; D'Souza D; Sullivan KP; Aldridge M; Waddington W; Gaze MN
J Nucl Med; 2011 Jul; 52(7):1041-7. PubMed ID: 21680680
[TBL] [Abstract][Full Text] [Related]
10. Initial Experience With Gallium-68 DOTA-Octreotate PET/CT and Peptide Receptor Radionuclide Therapy for Pediatric Patients With Refractory Metastatic Neuroblastoma.
Kong G; Hofman MS; Murray WK; Wilson S; Wood P; Downie P; Super L; Hogg A; Eu P; Hicks RJ
J Pediatr Hematol Oncol; 2016 Mar; 38(2):87-96. PubMed ID: 26296147
[TBL] [Abstract][Full Text] [Related]
11. (68)Ga-DOTATATE and (18)F-FDG PET/CT in Paraganglioma and Pheochromocytoma: utility, patterns and heterogeneity.
Chang CA; Pattison DA; Tothill RW; Kong G; Akhurst TJ; Hicks RJ; Hofman MS
Cancer Imaging; 2016 Aug; 16(1):22. PubMed ID: 27535829
[TBL] [Abstract][Full Text] [Related]
12. 68Ga-DOTATATE PET in neuroectodermal tumours: first experience.
Win Z; Al-Nahhas A; Towey D; Todd JF; Rubello D; Lewington V; Gishen P
Nucl Med Commun; 2007 May; 28(5):359-63. PubMed ID: 17414885
[TBL] [Abstract][Full Text] [Related]
13. 18F-FDG PET/CT and 123I-metaiodobenzylguanidine imaging in high-risk neuroblastoma: diagnostic comparison and survival analysis.
Papathanasiou ND; Gaze MN; Sullivan K; Aldridge M; Waddington W; Almuhaideb A; Bomanji JB
J Nucl Med; 2011 Apr; 52(4):519-25. PubMed ID: 21421719
[TBL] [Abstract][Full Text] [Related]
14. Brain Metastases of a Neuroendocrine Tumor Visualized by 68Ga-DOTATATE PET/CT.
Hoberück S; Michler E; Zöphel K; Platzek I; Kotzerke J; Brogsitter C
Clin Nucl Med; 2019 Jan; 44(1):50-52. PubMed ID: 30371585
[TBL] [Abstract][Full Text] [Related]
15. Comparison of 18 F-MFBG and 68 Ga-DOTATATE PET/CT in the Imaging of Metastatic Paraganglioma and Pheochromocytoma.
Deng M; Shu Q; Hu M; Chen Y; Cai L
Clin Nucl Med; 2022 Dec; 47(12):e735-e737. PubMed ID: 35777982
[TBL] [Abstract][Full Text] [Related]
16. Brain Metastasis of Medullary Thyroid Carcinoma Without Macroscopic Calcification Detected First on 68Ga-Dotatate and Then on 18F-Fluoride PET/CT.
Duarte PS; Marin JFG; De Carvalho JWA; Sapienza MT; Buchpiguel CA
Clin Nucl Med; 2018 Aug; 43(8):623-624. PubMed ID: 29894334
[TBL] [Abstract][Full Text] [Related]
17.
Şimşek DH; Şanlı Y; Kuyumcu S; Başaran B; Mudun A
Ann Nucl Med; 2018 May; 32(4):297-301. PubMed ID: 29468487
[TBL] [Abstract][Full Text] [Related]
18. [(68)Ga]DOTATATE PET/MRI and [(18)F]FDG PET/CT are complementary and superior to diffusion-weighted MR imaging for radioactive-iodine-refractory differentiated thyroid cancer.
Vrachimis A; Stegger L; Wenning C; Noto B; Burg MC; Konnert JR; Allkemper T; Heindel W; Riemann B; Schäfers M; Weckesser M
Eur J Nucl Med Mol Imaging; 2016 Sep; 43(10):1765-72. PubMed ID: 27059853
[TBL] [Abstract][Full Text] [Related]
19. Effect of thyroid-stimulating hormone in 68Ga-DOTATATE PET/CT of radioiodine-refractory thyroid carcinoma: a pilot study.
Almeida LS; Araújo MC; Zantut-Wittmann DE; Assumpção LV; Souza TF; Silva CM; Argenton JL; Santos AO; Mengatti J; Ramos CD; Etchebehere EC
Nucl Med Commun; 2018 May; 39(5):441-450. PubMed ID: 29543624
[TBL] [Abstract][Full Text] [Related]
20.
Shahrokhi P; Emami-Ardekani A; Harsini S; Eftekhari M; Fard-Esfahani A; Fallahi B; Karamzade Ziarati N; Akhlaghi M; Farzanefar S; Hashemi Taheri AP; Beiki D
Asia Ocean J Nucl Med Biol; 2020; 8(1):8-17. PubMed ID: 32064278
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]